Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 2,234 All time
- Disclosed funding
- $222.2B 1857 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| BE Bluecore EnergyCompany profile Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure | $40M | Seed — additional capital within USD50m financingSeed | Climate tech | United States | Investors Silverton PartnersLeadAct One Ventures +23Animal CapitalBAG CollectiveBorusan VenturesCapital FactoryCollab CapitalFortson VCHarlem CapitalHartBeat VenturesJoel EmbiidLMnT VenturesMaC VenturesMalik MonkMarkham Valley VenturesPrecursor VenturesRackhouse Venture CapitalScribble VenturesShare VenturesSlauson & Co.Symphony VenturesTaijuan WalkerVanderbilt UniversityVisible HandsX& | |
| MB Moonwalk BiosciencesCompany profile Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. | $70M | Series B | Biotech | United States | Investors | |
| F Fab2Company profile Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. | $500M | Series A | Hardware | United States | Investors | |
| BB BrainChild BioCompany profile BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. | $116M | Series A | Biotech | United States | Investors Undisclosed | |
| TI Tokoshie, Inc.Company profile The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models. The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models. | Undisclosed | FundingUndisclosed | AI | United States | Investors | |
| P ParlayXCompany profile ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. | $1.3M | Pre-SeedPre-seed | Fintech | United States | Investors | |
| GL Gimlet LabsCompany profile Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. | $300M | Series B | AI | United States | Investors | |
| CB Cloverleaf BioCompany profile Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. | $33M | Seed | Biotech | United States | Investors | |
| A AntiochCompany profile Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. | $32M | Series A | AI | United States | Investors | |
| E EmberosCompany profile Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms. Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms. | $5.5M | Seed | Enterprise software | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Y Combinator (YC)
Tractian, Blacksmith, Greptile
129rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
102rounds20led - 3General Catalyst
Tractian, Different, Baba
71rounds8led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
59rounds0led - 5Khosla Ventures
Arda Industries, Tolan
58rounds6led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.